Big Conversations: In-House Counsel Discuss the Past, Present, and Future of Biosimilars Market Entry in the EU and U.S. (Part 3)

In a continuation from Part 1 and Part 2, Goodwin and Bristows continue their discussion with senior in-house counsel at the forefront of the biosimilars industry to discuss the pace of biosimilars market entry in the EU and U.S., why it’s been so different in those two markets, and what the future holds. In the third of four segments, the panel covers topics including the rate of biosimilar application filings, dealing with competitors, and perceptions regarding differences among biosimilars.

Moderators: Huiya Wu (Partner, Goodwin), Dom Adair (Partner, Bristows)

Panelists: Rachel Moodie (Vice President of IP Biosimilars, Fresenius), Alastair Sayce (Lead of Biologics IP, Teva), and Neil Trueman (Chief International IP Counsel, Mundipharma)

“All biosimilars have to get over huge hurdles set by the regulators to show that they are as safe and as efficacious as the originator product.” –Rachel Moodie, Vice President of IP Biosimilars, Fresenius